# DYADIC INTERNATIONAL INC (DYAI) — capital_raise/atm_program [expired]
Source: sec.gov · situation sit_cb7f7d6472aaf4f4175e · public 5054183781855511613 · retrieved 2026-08-20T13:16:25.536Z

## Overview
Dyadic International, Inc. is a biological products company (SIC 2836) that develops enzyme technology and related products.

On August 13, 2026, Dyadic International, Inc. entered into a common stock purchase agreement to issue and sell 3,625,000 shares of common stock at $0.795 per share in a registered direct offering, and a concurrent private placement of warrants to purchase 3,625,000 shares at an exercise price of $0.84 per share, with warrants priced at $0.005 each. The aggregate gross proceeds from both offerings are expected to be approximately $2.9 million. Closing is expected on or about August 14, 2026, subject to customary closing conditions. The company intends to use net proceeds for general corporate purposes, including research and development, sales and marketing, general administrative expenses, working capital, capital expenditures, and potential acquisitions.

## Terms
- Counterparty: Certain investors (Common Stock Purchasers and Warrant Purchasers) · Deal value: $2.9M · Consideration: mixed · Price/share: $0.795

## Key dates
- Expected close 2026-08-14 · Expired 2026-08-14

## Timeline
- 2026-08-14 · 8-K (0001493152-26-038039): 8-K - DYADIC INTERNATIONAL INC — *Dyadic International, Inc. is a biological products company (SIC 2836) that develops enzyme technology and related products.* On August 13, 2026, Dyadic International, Inc. entered into a common stock purchase agreement to issue and sell 3,625,000 shares of common stock at $0.795 per share in a registered direct offering, and a concurrent private placement of warrants to purchase 3,625,000 shares at an exercise price of $0.84 per share, with warrants priced at $0.005 each. The aggregate gross proceeds from both offerings are expected to be approximately $2.9 million. Closing is expected on or about August 14, 2026, subject to customary closing conditions. The company intends to use net proceeds for general corporate purposes, including research and development, sales and marketing, general administrative expenses, working capital, capital expenditures, and potential acquisitions.
  https://www.sec.gov/Archives/edgar/data/1213809/0001493152-26-038039.txt

## Citations
- 0001493152-26-038039 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226038039